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Abstract
Background & Aims—Mitochondrial dysfunction has been implicated in various functional
disorders that are co-morbid to Irritable Bowel Syndrome (IBS) such as migraine, depression and
chronic fatigue syndrome. The aim of the current case-control pilot study was to determine if
functional symptoms in IBS show a maternal inheritance bias, and if the degree of this maternal
inheritance is related to mitochondrial DNA (mtDNA) polymorphisms.
Methods—Pedigrees were obtained from N=308 adult IBS patients, N=102 healthy controls, and
N=36 controls with Inflammatory Bowel Disease (IBD), all from Caucasian heritage, to determine
probable maternal inheritance. Two mtDNA polymorphisms (16519T and 3010A), which have
previously been implicated in other functional disorders, were assayed in mtDNA haplogroup H
IBS subjects and compared to genetic data from N=344 published haplogroup H controls.
Results—Probable Maternal Inheritance was found in 17.5% IBS, 2% healthy controls and 0%
IBD controls (p < 0.0001). No difference was found between IBS and control for 3010A, and a
trend was found for 16519T (p=.05). IBS with maternal inheritance were significantly more likely
to have the 16519T than controls (OR=5.8; 95%CI=1.5–23.1) or IBS without maternal inheritance
(OR=5.2; 95%CI=1.2–22.6).
Conclusions—This small pilot study shows that a significant minority (1/6) of IBS patients
have pedigrees suggestive of maternal inheritance. The mtDNA polymorphism 16519T, which has
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been previously implicated in other functional disorders, is also associated with IBS patients who
display maternal inheritance. These findings suggest that mtDNA-related mitochondrial
dysfunction may constitute a sub-group within IBS. Future replication studies in larger samples
are needed.
Keywords
Functional gastrointestinal disorders; genetics; cellular energy metabolism; comorbidity
Introduction
Irritable Bowel Syndrome (IBS) is a very common condition afflicting 10% of the
population1, and many patients struggle with co-morbid conditions such as fibromyalgia,
chronic fatigue syndrome, temporomandibular joint disorder, anxiety disorder, and
depression2. These conditions are all of “functional" origin, diagnosed based on a
constellation of clinical findings but lack clear biological markers. Functional disorders may
run in families, and respond to similar treatments (e.g., tricyclic antidepressants), suggesting
a shared genetic component and pathophysiology3–5. Many genes have been implied in each
of these disorders separately, but so far none of these can explain the overlap.
Defects in cellular energy metabolism have been observed in the brain or muscle of subjects
with migraine, cyclic vomiting syndrome, depression, and chronic fatigue syndrome6–9. The
vast majority of energy (ATP) is produced by sub-cellular organelles called mitochondria.
The mitochondria contain their own DNA (mtDNA) consisting of only 37 genes, all
involved in ATP synthesis. Mutations in these genes can lead to disease caused by low
cellular energy production10. mtDNA is inherited from the mother only, which opens the
possibility of examining maternal inheritance patterns as a way to examine if disease-
associated mtDNA polymorphisms may be present. In fact, IBS has been shown to be
aggregated more strongly in mothers than in fathers, which suggests a maternal inheritance
pattern could be present3.
Of particular note is that mtDNA disorders do not ‘breed true’, but are associated with
extraordinary phenotypic variation among affected individuals11. This means that many
different types of functional symptoms are common in these families, with each individual
having a unique set of such conditions. When multiple functional disorders are ascertained
for, preferential inheritance through the maternal line was reported in 20-60% of patients
with migraine12, cyclic vomiting syndrome13, depression14, 15 and complex regional pain
syndrome16.
Recently, two common mtDNA sequence variants (polymorphisms 3010A and 16519T)
have been associated with cyclic vomiting syndrome and migraine12. Camilleri and
colleagues17, found no association with IBS. However, they included all IBS patients rather
than focusing on the subgroup with likely maternal inheritance patterns, possibly
underestimating the effects of mtDNA in IBS.
In the current pilot study, we aimed to explore if functional symptoms are preferentially
inherited through the matrilineal line among IBS patients. We also examined if 3010A and
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16519T, may distinguish IBS patients with maternal inheritance patterns from IBS patients
without maternal inheritance patterns and controls. A last exploratory aim was to identify




IBS patients had a prior physician diagnosis of IBS, met the Rome III criteria for IBS and
had no other diagnoses that could cause bowel symptom (e.g., Crohn’s disease). Healthy
control subjects were free of any bowel disorders as well as manifestations suggestive of
possible mitochondrial dysfunction. Inflammatory Bowel Disease (IBD) control subjects
had a physician diagnosis of Ulcerative Colitis or Crohn’s disease as verified by one of the
investigators. IBS patients and healthy controls were recruited from 2009–2011 among
patients, faculty, staff and students at the University of North Carolina. IBD controls were
recruited among patients at the Gastroenterology clinics in the Medical College of
Wisconsin. The study was approved in 2008 by the Institutional Review Boards of the
University of North Carolina, Children’s Hospital Los Angeles and the Medical College of
Wisconsin.
Measures
Quantitative Pedigree Analysis—Detailed pedigrees were collected over the telephone
or in person per established protocol12, 16. In short, health information from all first and
second-degree relatives was obtained from the subject using a semi-structured interview (for
a copy of the interview see Higashimoto et al16). The average number of functional
conditions recorded among the matrilineal and non-matrilineal relatives were calculated and
compared to each other (“maternal inheritance ratio”). Pedigrees were labeled as “probable
maternal inheritance” if the average number of conditions per matrilineal relative was at
least 1.75 and functional conditions was at least 3-fold more common in matrilineal versus
non-matrilineal relatives (Maternal Inheritance Ratio ≥ 3.0). Pedigrees that did not qualify
for maternal inheritance were labeled as “probable non-maternal inheritance”.
Molecular Analyses—Saliva kits (Oragene; DNA Genotek Inc., Ottawa, ON, Canada) for
collecting mtDNA were sent to IBS subjects and returned by mail. DNA was isolated from
the saliva kits. In order to increase statistical power and assign appropriate controls, we
limited all analyses to haplogroup H. The mtDNA haplogroups denote the major groupings
of mitochondrial lineage sharing a similar maternal ancestor. Haplogroup H is the most
common among Americans (about 30%)18, show minor interfamilial sequence variation, and
previous investigations of mtDNA in functional symptoms have largely been limited to
haplogroup H12, 17.
Haplogroup H was defined in the conventional manner as the presence of a C at position
7028 by polymerase chain reaction-restriction fragment length polymorphism (RFLP)—
7028: AluI F TTTCGGTCACCCTGAAGTTTA, and R AGCGAAGGCTTCTCAAATCAT.
Subjects with 7028C (haplogroup H) were tested for the 16519C>T and 3010G>A
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polymorphisms by PCR/restriction fragment length polymorphism (16519: HaeIII forward
GGATGACCCCCCTCAGATA, reverse CTTATTTAAGGGGAACGTG; 3010: BccI
forward CATGCTAAGACTTCACCA, reverse TCGTTGAACAAACGAACC).
In 10 haplogroup H IBS patients with the highest degree of maternal inheritance complete
cyclosequencing of the mtDNA was performed by a commercial laboratory (Eton, San
Diego, CA). The entire mtDNA was amplified using 30 overlapping primer sets as described
previously19. Individual sequences were assembled, aligned and compared on Sequencher®
software (Gene Codes Corp., Ann Arbor, MI, USA) vs. our reference sequence (revised
Cambridge Reference Sequence- MITOMAP10). Complete mtDNA sequences were
assigned to haplogroups and clades according to Phylotree.org Build 1419 (http://
www.phylotree.org). Sequences were assigned to the closest matching halogroup/clade.
Mitochondrial DNA rearrangements were investigated in the aforementioned 10 haplogroup
H IBS patients with the highest degree of maternal inheritance using Long-Range PCR20.
Near complete mtDNA was amplified using two primers LR321
TGGCCACAGCACTTAAACACATCTC and LR16215
TGCTGTACTTGCTTGTAAGCATGGG. PCR amplifications were the resolved on a 1.0%
agarose gel.
Statistical analyses—Data analyses were performed with SPSS Statistics 19 (IBM).
Percentage of pedigrees with a maternal inheritance patterns was compared between IBS
patients and controls with Chi2-test. Odds ratios were calculated to compare presence of
3010A and 16519T in haplogroup H IBS patients compared to genetic data from N= 344
published controls12. For the genetic analyses, missing data was not included in the
analyses.
Sequence variants in the 10 haplogroup H IBS subjects with the highest degrees of probable
maternal inheritance were compared to the most common haplogroup H nucleotide sequence
generated from 344 complete mtDNA published sequences. These sequences were
ascertained from individuals as part of a population or control study from Europe or North
America. To reduce potential bias, no samples were included that were associated with any
known illness or symptoms, from self-selected groups (commercial heritage testing), and
from islands with small founding and/or geographically isolated populations (Iceland and
Sardinia).
Results
Pedigrees were obtained from N=102 healthy controls N=36 IBD patients and N=308 adult
IBS patients (for demographic information see Table 1). No differences were found in age
and gender between these groups. Probable maternal inheritance was found in 17.5% of IBS
patients versus in 2% of healthy controls (p < 0.0001) and 0% of 36 IBD controls (p < .
0001). An example of a pedigree with maternal inheritance is available in supplementary
Figure a. In addition, supplementary Figure b shows that the majority of control patients
have few maternal symptoms per relative and low maternal inheritance ratios, while a
subgroup of IBS patients score high on these.
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DNA samples were missing or of low quality for 13 IBS patients, leaving mtDNA samples
for N=295 IBS patients, and N=86 (29.2%) belonged to haplogroup H. In this group, 3010A
was as common as among the 344 population controls (27.4% versus 33.4%; OR=0.74, 95%
CI 0.44–1.23), but a trend (p=.05) was found for 16519T (38.4% versus 28.5%; OR=1.6,
95% CI .99–2.63). IBS patients demonstrating probable maternal inheritance were
significantly more likely to have the 16519T polymorphism than IBS patients without
maternal inheritance or controls (see Figure 1).
Full mtDNA sequences of ten IBS patients who had the highest maternal inheritance ratio,
identified between 1-11 mtDNA variants per person (see Table 2). Not one variant was
shared among all subjects, although 16519T was present in five out of these ten subjects. Of
interest, was a high rate of variants in region 110-567: In the IBS patients, 40% had 3 or
more variants in this region versus 13.9% in the controls (Chi2=6.64; p < .01).
Discussion
The current pilot study suggests a possible role for mitochondrial DNA in IBS. Our findings
indicate that functional symptoms are preferentially maternally inherited in a subset of IBS
patients. In addition, the 16519T sequence variant, which has been associated with the
functional conditions of migraine and cyclic vomiting syndrome12, may also be associated
with the 1/6th of IBS patients who show a maternal inheritance pattern of functional
symptoms. The association with all cases of IBS was weak (p=.05), replicating the non-
significant results reported earlier17. These findings suggest that a defect in energy
metabolism may play a role in IBS among a limited, but substantial, subset of patients.
Validation in larger samples are needed.
The location of the 16519T polymorphism may indicate its possible role in IBS and other
co-morbid functional disorders. 16519T is located in the 1-kb non-coding mtDNA control
region not far from the origin of heavy-strand replication and putative membrane-attachment
site10. The control region does not code for proteins or RNA, but replication of mtDNA
starts in this region and, therefore, 16519T may be involved in the number or mtDNA
genomes available in a cell (cells contain many copies of mtDNA). Future studies are
needed to determine the physiological effects of the presence of 16519T.
No reported or obvious disease-associated sequence variants were found on full mtDNA
sequencing of the 10 most extreme probable maternally inherited IBS families other than a
high prevalence of 16519T as noted above. However, polymorphisms in the 3 side of the
control region (#110–567) were far more common among the patient than among the control
sequences. A recent study in IBS patients found a similar result in which they reported
increased polymorphisms (authors only studied the MT-ATP6-8 regions), but no one
polymorphism distinguished IBS patients from controls21. The area identified in the current
study, starting at the H-strand replication origin, includes promoters for both strands and
conserved sequence blocks. Their locations, plus that of 16519 suggests pathology that
predisposes towards functional disease is likely a result of a decreased copy number of
mitochondrial-encoded respiratory chain subunits.
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If the role of mtDNA in IBS is correct, as suggested by these pilot data, low cellular energy
metabolism can contribute towards the development of functional symptoms as varied as
gastrointestinal problems, headaches and fatigue. Thus, it may be a mechanism by which
comorbid functional symptoms in IBS can be explained. The cause of overlapping co-
morbid disorders in IBS is likely complicated and has been associated with increased
attention to bodily symptoms, mental health conditions, and wide spread neural
hypersensitivity2, 22 some of which are common in patients diagnosed with genetic
mitochondrial disorders as well6, 23. Mitochondrial dysfunction warrants investigation as
another possible cause for co-morbidity.
The current study has several limitations. First, we studied a relatively small set of
haplogroup H patients which yields issues with power, generalizability, and the inability to
examine confounders such as age and gender. Second, the control sample for the genetic
analyses was drawn from published resources and these samples were not collected for our
purpose. Lastly, the quantitative pedigree, to establish phenotype has been used in many
other published studies, but almost all of these are among children. Given that both our and
pediatric studies have found a positive association with 16519T, suggests that the interview
is sensitive in adults as well. More studies are needed to replicate the findings of this small
pilot study before any definitive conclusions can be drawn about the role of mitochondrial
dysfunction in IBS.
In conclusion, our data suggest a possible role of mitochondrial dysfunction in a subset of
IBS patients. Although our study is small and has many limitations, the findings provide
rationale for further investigation into mitochondrial dysfunction in IBS. Mitochondrial-
targeted therapies have shown some initial promising efficacy in migraine24–27,
fibromyalgia28, 29, and cyclic vomiting syndrome30, 31. Thus, investigation of the role of
mitochondrial dysfunction in IBS could in the future make an important impact on the care
of this disorder.
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mtDNA polymorphism 16519T is associated with IBS and maternal inheritance.
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Age Mean= 40.1 Mean=47.2 Mean=38.7
Gender 88.6% female 63.4% female 91.2% female
Race 100% Caucasian 100% Caucasian 100% Caucasian











Significant higher compared to IBD and HC (p < .001) by one-way anova.
**
Significant higher compared to IBD (p < .01) by one-way anova.
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Table 2












4 T239C 302.1 (ins) 302.2 (ins) 302.3 (ins) G366A G3915A
G9380A T11253C T16298C T16362C A16482G C16519T
2
12
1 T152C 302.3 (ins) C3393T C3992T T4418C T6776C 10754C
11017G C11563T T12502G T14180C C16519T
3
8
4 302.2 (ins) 302.3 (ins) T309C G316C G366A G3010A G6722A
C15088T
4 6 2 C151T 302.1 (ins) 302.3 (ins) G3010A, T10687T/C C16519T
5
9
4 302.2 (ins) 302.3 (ins) T309C C456T C534A T4336C C15833T
T16304C C16519T
6 10 4 T146CT195C 302.2 (ins) 302.3 (ins) C456T G5471A A8343G
A14497G T16304C C16519T
7 3 1 302.2 (ins) 302.3 (ins) T14470A
8 5 1 C186A 302.3 (ins) G1438A T3396C G4769A
9
9




1 A73G 302.1 (ins), 302.3 (ins) G3010A A8338T G9053A T13830C
A16051G A16162G C16465T
*
302.3 (ins) occurs in all samples and has therefore been removed from this count of variants.
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